Cell therapy for cardiovascular disease

Jonathan R Murrow, Saurabh S. Dhawan, Arshed A. Quyyumi

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Advances in diagnosis and treatment have dramatically impacted morbidity and mortality from cardiovascular disease over the past several decades. 1 The discovery in 1960 of stem cells capable of regeneration and repair sparked interest in a new mode of therapy for heart disease beyond pharmaceuticals and cardiac devices.2 Over the past 10 years, work has focused on five key cell types - the endothelial mononuclear progenitor cell, the autologous skeletal myoblast, the allogeneic mesenchymal stem cell, the resident cardiac stem cell, and the human embryonic stem cell - as potential therapeutic agents, which may further contribute to gains in treating cardiovascular disease. This chapter aims to review these cell types, their preclinical underpinnings, the nascent clinical studies, and limitations observed in their use.

Original languageEnglish (US)
Title of host publicationAdvances in Vascular Medicine
PublisherSpringer
Pages131-151
Number of pages21
ISBN (Print)9781848826366
DOIs
StatePublished - Dec 1 2010
Externally publishedYes

Fingerprint

Cell- and Tissue-Based Therapy
Cardiovascular Diseases
Stem Cells
Skeletal Myoblasts
Mesenchymal Stromal Cells
Regeneration
Heart Diseases
Therapeutics
Morbidity
Mortality
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Murrow, J. R., Dhawan, S. S., & Quyyumi, A. A. (2010). Cell therapy for cardiovascular disease. In Advances in Vascular Medicine (pp. 131-151). Springer. https://doi.org/10.1007/978-1-84882-637-3_8

Cell therapy for cardiovascular disease. / Murrow, Jonathan R; Dhawan, Saurabh S.; Quyyumi, Arshed A.

Advances in Vascular Medicine. Springer, 2010. p. 131-151.

Research output: Chapter in Book/Report/Conference proceedingChapter

Murrow, JR, Dhawan, SS & Quyyumi, AA 2010, Cell therapy for cardiovascular disease. in Advances in Vascular Medicine. Springer, pp. 131-151. https://doi.org/10.1007/978-1-84882-637-3_8
Murrow JR, Dhawan SS, Quyyumi AA. Cell therapy for cardiovascular disease. In Advances in Vascular Medicine. Springer. 2010. p. 131-151 https://doi.org/10.1007/978-1-84882-637-3_8
Murrow, Jonathan R ; Dhawan, Saurabh S. ; Quyyumi, Arshed A. / Cell therapy for cardiovascular disease. Advances in Vascular Medicine. Springer, 2010. pp. 131-151
@inbook{20ca24e4e0d54cf09da84eb083b9f415,
title = "Cell therapy for cardiovascular disease",
abstract = "Advances in diagnosis and treatment have dramatically impacted morbidity and mortality from cardiovascular disease over the past several decades. 1 The discovery in 1960 of stem cells capable of regeneration and repair sparked interest in a new mode of therapy for heart disease beyond pharmaceuticals and cardiac devices.2 Over the past 10 years, work has focused on five key cell types - the endothelial mononuclear progenitor cell, the autologous skeletal myoblast, the allogeneic mesenchymal stem cell, the resident cardiac stem cell, and the human embryonic stem cell - as potential therapeutic agents, which may further contribute to gains in treating cardiovascular disease. This chapter aims to review these cell types, their preclinical underpinnings, the nascent clinical studies, and limitations observed in their use.",
author = "Murrow, {Jonathan R} and Dhawan, {Saurabh S.} and Quyyumi, {Arshed A.}",
year = "2010",
month = "12",
day = "1",
doi = "10.1007/978-1-84882-637-3_8",
language = "English (US)",
isbn = "9781848826366",
pages = "131--151",
booktitle = "Advances in Vascular Medicine",
publisher = "Springer",

}

TY - CHAP

T1 - Cell therapy for cardiovascular disease

AU - Murrow, Jonathan R

AU - Dhawan, Saurabh S.

AU - Quyyumi, Arshed A.

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Advances in diagnosis and treatment have dramatically impacted morbidity and mortality from cardiovascular disease over the past several decades. 1 The discovery in 1960 of stem cells capable of regeneration and repair sparked interest in a new mode of therapy for heart disease beyond pharmaceuticals and cardiac devices.2 Over the past 10 years, work has focused on five key cell types - the endothelial mononuclear progenitor cell, the autologous skeletal myoblast, the allogeneic mesenchymal stem cell, the resident cardiac stem cell, and the human embryonic stem cell - as potential therapeutic agents, which may further contribute to gains in treating cardiovascular disease. This chapter aims to review these cell types, their preclinical underpinnings, the nascent clinical studies, and limitations observed in their use.

AB - Advances in diagnosis and treatment have dramatically impacted morbidity and mortality from cardiovascular disease over the past several decades. 1 The discovery in 1960 of stem cells capable of regeneration and repair sparked interest in a new mode of therapy for heart disease beyond pharmaceuticals and cardiac devices.2 Over the past 10 years, work has focused on five key cell types - the endothelial mononuclear progenitor cell, the autologous skeletal myoblast, the allogeneic mesenchymal stem cell, the resident cardiac stem cell, and the human embryonic stem cell - as potential therapeutic agents, which may further contribute to gains in treating cardiovascular disease. This chapter aims to review these cell types, their preclinical underpinnings, the nascent clinical studies, and limitations observed in their use.

UR - http://www.scopus.com/inward/record.url?scp=84892106608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892106608&partnerID=8YFLogxK

U2 - 10.1007/978-1-84882-637-3_8

DO - 10.1007/978-1-84882-637-3_8

M3 - Chapter

AN - SCOPUS:84892106608

SN - 9781848826366

SP - 131

EP - 151

BT - Advances in Vascular Medicine

PB - Springer

ER -